TREM2 and early-onset autosomal dominant Alzheimer disease: Similar to ATV:4D9, ATV: TREM2, an antibody targeting human TREM2, demonstrated increased microglial activity and cerebral glucose metabolism in the 5×FAD mouse model compared to the isotype control antibody (ATV: ISO) group, suggesting a potentially positive impact on the treatment of Alzheimer’s disease (AD) (147).